Wells Fargo & Company Longeveron Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$1.25 - $2.51 $5,692 - $11,430	4,554 Added 3252.86%	4,694 $6,000
Q3 2023 Nov 13, 2023	BUY	$2.15 - $3.59 $212 - $355	99 Added 241.46%	140 $0
Q2 2023 Aug 15, 2023	BUY	$2.52 - $4.0 $7 - $12	3 Added 7.89%	41 $0
Q1 2023 May 12, 2023	BUY	$2.66 - $4.36 $2 - $4	1 Added 2.7%	38 $0
Q4 2022 Feb 13, 2023	BUY	$2.81 - $39.7 $2 - $39	1 Added 2.78%	37 $0
Q3 2022 Nov 14, 2022	BUY	$3.97 - $42.7 $15 - $170	4 Added 12.5%	36 $0
Q2 2022 Aug 12, 2022	BUY	$5.93 - $15.61 $23 - $62	4 Added 14.29%	32 $0
Q1 2022 May 16, 2022	BUY	$5.06 - $13.8 $45 - $124	9 Added 47.37%	28 $0
Q4 2021 Feb 14, 2022	BUY	$2.92 - $42.3 $2 - $42	1 Added 5.56%	19 $0
Q3 2021 Nov 15, 2021	SELL	$3.4 - $8.3 $3 - $8	-1 Reduced 5.26%	18 $0
Q2 2021 Aug 16, 2021	BUY	$5.2 - $8.13 $10 - $16	2 Added 11.76%	19 $0
Q1 2021 May 13, 2021	BUY	$5.66 - $8.45 $96 - $143	17 New	17 $0

581

Ticker LGVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,925,940
Market Cap $12.4M
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.